The $138.7M raise eliminates near-term going concern risk and funds the entire BETR-001 clinical program through Phase 2. Watch for IND filing in Q1 2027 and resolution of the director's convertible debenture dispute. Massive dilution (shares outstanding increased ~4x) caps near-term upside but de-risks the pipeline catalyst.
Price Chart
Executive Summary
BetterLife Pharma filed its Q2 FY2027 interim financials (period ended July 31, 2026) alongside a subsequent $138.7M public offering on September 17, 2026. The company remains pre-revenue with a net loss of $2.7M for H1 FY2027 (vs $0.7M YoY), an accumulated deficit of $122.8M, and a going concern qualification. The massive September equity raise funds Phase 1-2 clinical trials for lead candidate BETR-001 (2-bromo-LSD) targeting cluster headache and migraine, with IND filing targeted for Q1 2027. The offering transforms the balance sheet but massively dilutes existing shareholders.
Key Facts
- Closed public offering on September 17, 2026 for gross proceeds of $138,748,920, issuing 447,041,840 common shares at $0.25 and 107,958,160 pre-funded warrants at $0.24999
- Net loss for six months ended July 31, 2026 was $2,704,167 vs $711,166 in prior year period
- Accumulated deficit reached $122,785,512 as of July 31, 2026
- Cash balance improved from $12,570 at Jan 31, 2026 to $973,593 at July 31, 2026, before the September offering
- Working capital deficiency of $7,631,319 at July 31, 2026
- Lead drug candidate BETR-001 (2-bromo-LSD) is a non-hallucinogenic neuroplastogen targeting cluster headache and migraine, currently at preclinical stage
- IND filing for BETR-001 targeted for Q1 2027, with Phase 1A/1B/2 trials budgeted at ~$105M
- Company issued $2M convertible debenture to a director in June 2026; post-period dispute over repayment/conversion remains unresolved
- Outstanding shares ballooned from ~152M at Jan 31, 2026 to 618M post-offering (plus 108M pre-funded warrants and 75M warrants)
Financial Impact
$138.7M gross proceeds from public offering transforms liquidity; net loss run-rate ~$5.4M annualized pre-offering; ~$105M budgeted for clinical development
Risk Factors
- Massive shareholder dilution: shares outstanding increased from ~152M to ~618M plus 108M pre-funded warrants
- BETR-001 is preclinical with no guarantee of clinical success or regulatory approval
- Unresolved dispute with director over $2M convertible debenture repayment vs conversion
- Company has no revenue and no path to profitability in the near term
- Pre-funded warrants at $0.00001 exercise price represent additional overhang
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001477932-26-005911 |
| Document: betrf_ex991.htm | 0001477932-26-005911 |
| Document: betrf_6k.htm | 0001477932-26-005911 |
| Document: betrf_ex993.htm | 0001477932-26-005911 |
| Document: betrf_ex994.htm | 0001477932-26-005911 |
| Document: 0001477932-26-005911-index-headers.html | 0001477932-26-005911 |
| Document: 0001477932-26-005911-index.html | 0001477932-26-005911 |
| Document: 0001477932-26-005911.txt | 0001477932-26-005911 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 6-K | $0.2410 $0.1920 | ▼ −20.33% | ▼ −22.25% | $0.1600 (−33.61%) |
Sep 22, 2026 5w ago | SC 13G | $0.2400 $0.2410 | ▲ +0.42% | ▲ +1.09% | $0.1600 (−33.33%) |
Sep 15, 2026 6w ago | 6-K | $0.2740 $0.2217 | ▼ −19.09% | ▼ −19.91% | $0.1600 (−41.61%) |
Sep 11, 2026 6w ago | 6-K | $0.2300 $0.2550 | ▲ +10.87% | ▲ +11.09% | $0.1600 (−30.43%) |
Aug 24, 2026 9w ago | 6-K | $0.2240 $0.2195 | ▼ −2.01% | ▼ −2.48% | $0.1600 (−28.57%) |
Jun 26, 2026 17w ago | 6-K | $0.1110 $0.1310 | ▲ +18.02% | ▲ +15.85% | $0.1600 (+44.14%) |
Apr 13, 2026 28w ago | 6-K | $0.0410 $0.0480 | ▲ +17.07% | ▲ +13.78% | $0.1600 (+290.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers